Analytical Data
-
Gene name
PNMA1
- Application
-
Alternative Names
PNMA1；MA1；Paraneoplastic antigen Ma1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8ND90
-
Expression Region
1-353aa
-
AA Sequence
MAMTLLEDWCRGMDVNSQRALLVWGIPVNCDEAEIEETLQAAMPQVSYRMLGRMFWREENAKAALLELTGAVDYAAIPREMPGKGGVWKVLFKPPTSDAEFLERLHLFLAREGWTVQDVARVLGFQNPTPTPGPEMPAEMLNYILDNVIQPLVESIWYKRLTLFSGRDIPGPGEETFDPWLEHTNEVLEEWQVSDVEKRRRLMESLRGPAADVIRILKSNNPAITTAECLKALEQVFGSVESSRDAQIKFLNTYQNPGEKLSAYVIRLEPLLQKVVEKGAIDKDNVNQARLEQVIAGANHSGAIRRQLWLTGAGEGPAPNLFQLLVQIREEEAKEEEEEAEATLLQLGLEGHF
-
Molecular Weight
46.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PNMA1 (Paraneoplastic Ma Antigen 1) is a protein that has garnered significant attention in the field of cancer research due to its association with paraneoplastic syndromes and potential role as a tumor marker. Initially identified as an autoantigen in patients with malignancies, particularly small cell lung cancer (SCLC), PNMA1 is implicated in the development of immune responses against tumors. Research has revealed that aberrant expression of PNMA1 can trigger autoimmune responses, leading to neurological complications in cancer patients. The investigation of PNMA1 and its recombinant forms aims to elucidate its biological functions, interactions, and the mechanisms underlying its role in cancer progression and the immune response. Recombinant PNMA1 proteins serve as valuable tools for studying the protein's immunogenicity and have potential applications in developing diagnostic assays and immunotherapies. Understanding PNMA1's structure-function relationship and its involvement in tumorigenesis could provide insights into novel therapeutic strategies and improve patient outcomes in cancers associated with this autoantigen.
